Feasibility and efficacy of a home-based randomized intervention of up to two classes of anti-hypertensive medications versus up to two fewer classes of anti-hypertensive medications among older patients with multimorbidity or polypharmacy

niversity of Oxford0 个研究点目标入组 230 人开始时间: 2020年12月1日最近更新: 2023年8月28日

适应症

试验速览

•1. Age 65 years or more
•2. Having at least three chronic diseases or taking at least five non-antihypertensive drugs
•3. Baseline office systolic BP in the range of 115-165 mmHg (or home systolic BP of 110-160 mmHg)
•4. Willingness to have anti-hypertensive medication modified (increased, decreased or left unchanged) by trial team for the duration of the trial
•5. Willingness to register with the specified on-line pharmacy service to facilitate remote dispensing of anti-hypertensive medication and period sharing of participants prescription list
•6. Willingness and ability to monitor BP at home
•7. Participant is willing and able to give informed consent for participation in the trial
•8. Participant’s or carer’s ability to understand English language is required to operate the IT-enabled (web-based) system

•1. Previous admission to hospital with primary diagnosis of heart failure or known systolic heart failure
•2. Self-reported symptomatic orthostatic hypotension
•3. Pre-existing anti-hypertensive treatment, or baseline BP prohibit the achievement of the minimum required change in anti-hypertensive drugs defined as:
•3.1. Office systolic BP 155 to 165 mmHg and on three or more anti-hypertensive medications
•3.2. Office systolic BP 115 to 124 mmHg and no anti-hypertensive medications
•4. Routine use of a dosset box or NOMAD box to help manage medications
•5. No reliable 4G mobile or WiFi network connectivity at home
•6. Lack of uncertainty in the opinion of the Investigator for changing BP drug treatment (e.g., any other significant disease, which, in the opinion of the Investigator, may either put the participant at risk because of participation in the trial, or the participant’s ability to participate in the trial)
•7. Current participation in any other research trial that investigates blood pressure management

发起方